Detail akcie Eli Lilly online

Business Summary: Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
Financial Summary: BRIEF: For the six months ended 30 June 2025, Eli Lilly And Co revenues increased 41% to $28.29B. Net income increased 62% to $8.42B. Revenues reflect Diabetes-Mounjaro segment increase of 85% to $9.04B, Diabetes-Zepbound segment increase from $1.76B to $5.69B, U.S. segment increase of 43% to $19.3B, Europe segment increase of 74% to $4.96B. Net income benefited from Asset Impairment, Restructuring, and decrease of 92% to $35M (expense).